Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax
← catalyst calendarNCT07478471 · readout ≤ 1,381 d
Sponsored by Emergent BioSolutions (industry) · EBS — their whole pipeline →. With Centers for Disease Control and Prevention, Department of Health and Human Services.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
10estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | May 2027 | estimated | When the study began enrolling |
| Primary completion | May 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Infections, Bacterial
Intervention
- Biological: Collection of samples
Primary outcomes
what the primary-completion date above is the date OFClinical Benefit of Raxibacumab for Patients with Confirmed Systemic Anthrax Disease
measured Up to Day 29
Clinical Benefit of Raxibacumab for Patients with Confirmed Systemic Anthrax Disease
measured Up to Day 29
Clinical Benefit of Raxibacumab for Patients with Confirmed Systemic Anthrax Disease
measured Up to Day 29
Permalink · EBS's whole pipeline · Catalyst calendar · Every registered study · What changed